Detection and prediction of active tuberculosis disease by a whole-blood interferon-γ release assay in HIV-l-infected individuals

Clinical Infectious Diseases

Volumn 48, Issue 7, 2009, Pages 954-962

  Aichelburg, Maximilian C ^a   Rieger, Armin ^a   Breitenecker, Florian ^a   Pfistershammer, Katharina ^a   Tittes, Julia ^a   Eltz, Stephanie ^a   Aichelburg, Alexander C ^c   Stingl, Georg ^a   Makristathis, Athanasios ^b   Kohrgruber, Norbert ^a,d,e  

^a Department of Dermatology   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c OTTO WAGNER HOSPITAL   (Austria)

^d WILHELMINEN HOSPITAL   (Austria)

^e Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK FACTOR; SCREENING TEST; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; AFRICA; AUSTRIA; CD4 LYMPHOCYTE COUNT; CONTINENTAL POPULATION GROUPS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; YOUNG ADULT;

EID: 63649149534     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597351     Document Type: Article

References (39)

1. Corbett EL, Watt CJ, Walker N, et al The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-21.
2. World Health Organization (WHO). Global tuberculosis control: surveillance, planning, financing. WHO report 2007. Geneva, Switzerland: WHO, 2007.
3. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005; 19:1113-24.
4. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53:1-112.
5. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-35.
6. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus: Uganda-Case Western Reserve University Research Collaboration. N Engl J Med 1997; 337:801-8.
7. Huebner RE, Schein ME, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993; 17:968-75.
8. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192-204.
9. Menzies D. Interpretation of repeated tuberculin tests: boosting, conversion, and reversion. Am J Respir Crit Care Med 1999; 159:15-21.
10. Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with Mycobacterium tuberculosis. Clin Infect Dis 1994; 19:26-32.
11. Johnson JL, Nyole S, Okwera A, et al. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans: the Uganda-Case Western Reserve University Research Collaboration. Am J Respir Crit Care Med 1998; 158:1790-6.
12. Chaisson RE, Keruly JC, McAvinue S, Gallant JE, Moore RD. Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:455-9.
13. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-104.
14. Arend SM, van Meijgaarden KE, de Boer K, et al. Tuberculin skin testing and in vitro T cell responses to ESAT-6 and culture filtrate protein 10 after infection with Mycobacterium marinum or M. kansasii. J Infect Dis 2002; 186:1797-807.
15. Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: an interferon-γ-based assay using new antigens. Am J Respir Crit Care Med 2004; 170:59-64.
16. Detjen AK, Keil T, Roll S, et al. Interferon-γ release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45:322-8.
17. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infect Dis 2006; 43:1540-6.
18. Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 2007; 30:945-50.
19. Pai M, Menzies D. Interferon-γ release assays: what is their role in the diagnosis of active tuberculosis? Clin Infect Dis 2007; 44:74-7.
20. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-γ release assay for detection of active tuberculosis. Clin Infect Dis 2007; 44:69-73.
21. Mazurek GH, Weis SE, Moonan PK, et al. Prospective comparison of the tuberculin skin test and 2 whole-blood interferon-gamma release assays in persons with suspected tuberculosis. Clin Infect Dis 2007; 45:837-45.
22. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosis of tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004; 364:2196-203.
23. Vincenti D, Carrara S, Butera O, et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 2007; 150:91-8.
24. World Medical Organization. Declaration of Helsinki. BMJ 1996; 313:1448-9.
25. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-47.
26. QuantiFERON-CMI [package insert], Carnegie, Victoria, Australia: Cellestis, 2003. Available at: http://www.cellestis.com/IRM/Company/ShowPage. aspx?CPID = 1170. Accessed 8 December 2005.
27. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17:857-72.
28. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
29. Pai M, Lewinsohn DM. Interferon-γ assays for tuberculosis: is anergy the Achilles' heel? Am J Respir Crit Care Med 2005; 172:519-21.
30. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16:2285-93.
31. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161:1376-95.
32. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-γ assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008; 177:1164-70.
33. Dheda K, Lalvani A, Miller RF, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 2005; 19:2038-41.
34. Rangaka MX, Diwakar L, Seldon R, et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis 2007; 44:1639-46.
35. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res 2006; 7:56.
36. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175:514-20.
37. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175:737-42.
38. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-γ release assay in Zambian adults with active tuberculosis. PLoS ONE 2008; 3:e2489.
39. Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents. Department of Health and Human Services. 7 April 2005: 1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL. pdf. Accessed 28 March 2006.